20-F: Meihua International Reports Fiscal 2024 Results Amidst Nasdaq Compliance Challenge and Ongoing Legal Battle

Meihua International Medical Technologies Co., Ltd. filed its annual report detailing slightly lower revenues and a 7% drop in net income for fiscal year 2024, alongside challenges including Nasdaq minimum bid price non-compliance and a significant legal contingency.

Summary

• Meihua International Medical Technologies Co., Ltd., a Cayman Islands holding company operating primarily in China, reported its financial results for the fiscal year ended December 31, 2024.
• The company specializes in the research, development, manufacturing, and sale of Class I, II, and III disposable medical devices, offering both its own branded products and sourced products through a one-stop service model.
• Total revenues for 2024 were $96.91 million, a slight decrease from $97.10 million in 2023, primarily attributed to the disposal of subsidiary Hainan Guoxie.
• Net income decreased by approximately 7% to $10.84 million in 2024 from $11.59 million in 2023, mainly due to increased operating expenses, particularly legal costs associated with ongoing litigation.
• Gross profit remained relatively stable at $33.30 million in 2024 compared to $33.20 million in 2023, with a consistent gross profit margin of 34%.
• The company continues to face risks related to its operations in China, regulatory oversight, market competition, and internal controls.
• A material weakness in internal control over financial reporting related to insufficient accounting personnel with U.S. GAAP knowledge persisted as of December 31, 2024.
• The company received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement in December 2024 and is working towards regaining compliance.
• Significant events included the completion of a $6 million convertible note financing in January 2024 (notes subsequently converted), the deconsolidation of Hainan Guoxie, an investment in Jiangsu Guomai, and the initiation of a share repurchase program.

Sentiment

Score: 3

Explanation: Declining net income in FY24, Nasdaq non-compliance, unresolved material weakness in internal controls, significant legal contingency, and the historical fraud incident create a negative sentiment, outweighing positives like the share repurchase plan and strategic investments.

Positives

• Gross profit margin remained stable at 34% year-over-year.
• The company successfully raised $5.58 million (net ~$4.8M) through convertible notes in early 2024, which were subsequently converted to equity, potentially strengthening the balance sheet.
• A share repurchase plan of up to $3 million was authorized, indicating management's confidence or an attempt to support the share price.
• The company made a strategic investment of $13.7 million for a 40% stake in Jiangsu Guomai Medical Equipment Co., Ltd.
• Research and development investment increased by 26% year-over-year, suggesting a focus on future product development.
• The company maintains a diverse product portfolio with 1,727 products and a large distribution network including 4,859 independent sales agents and over 4,000 distributors.
• The company claims a leading position in Touqiao Town, a major medical device hub in China.
• The company possesses necessary Class I, II, and III medical device qualifications in China, CE certification, and FDA registration for certain products.

Negatives

• Total revenues decreased slightly by $0.19 million in 2024 compared to 2023.
• Net income decreased by 7% in 2024 compared to 2023.
• Basic earnings per share declined from $0.49 in 2023 to $0.40 in 2024.
• The company received a Nasdaq notification for non-compliance with the minimum bid price requirement, risking potential delisting.
• A material weakness in internal controls over financial reporting related to inadequate U.S. GAAP expertise remains unresolved.
• The company is involved in significant litigation (Zhu Cheng v. Jiangsu Yada et al.) with an estimated contingent liability of $1.33 million recorded, stemming from a court ruling against its subsidiary for RMB 17 million plus interest.
• General and administrative expenses increased significantly by 19% due to legal costs.
• The company disclosed a historical incident from 2022 involving potential fraud by Tai He International Group Limited, resulting in write-offs exceeding $7 million in FY2022 and reputational risk.
• Accounts receivable remain high at $78.66 million, representing a significant portion of annual revenue.
• The company faces concentration risk with its top five customers contributing 41.90% of revenue in 2024.
• Operations are heavily concentrated in China, exposing the company to significant regulatory, economic, and political risks specific to the PRC.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price requirement could lead to delisting.
• The ongoing material weakness in internal controls could lead to financial misstatements and impacts reliability.
• The pending appeal in the Zhu Cheng litigation could result in significant financial liability if unsuccessful.
• Potential shareholder litigation or regulatory action related to the historical Tai He fraud incident and disclosure failures.
• Dependence on key customers; loss of top customers could significantly impact revenue (top 5 customers were 41.90% of 2024 revenue).
• Intense competition within the medical device industry, particularly from larger companies with greater resources and potentially higher-margin products.
• Risks associated with operating in China, including complex and evolving regulations, potential government intervention, cybersecurity and data privacy laws (including CAC reviews), foreign exchange controls, and legal system uncertainties.
• Uncertainty regarding the PCAOB's ability to inspect the company's auditor in the future, potentially triggering HFCAA delisting provisions (though the current auditor is US-based and inspectable).
• Fluctuations in raw material costs (rubber, PE, polypropylene, etc.) could impact profitability.
• Reliance on suppliers without long-term contracts poses risks of supply disruption or price increases.
• Potential product quality and safety issues could lead to liability claims, reputational damage, and regulatory action.
• Challenges in collecting large accounts receivable balances ($78.66 million as of Dec 31, 2024).
• The controlling shareholder (Mr. Yongjun Liu, ~50%) has significant influence, potentially leading to actions not aligned with minority shareholders' interests.
• Foreign exchange rate fluctuations between RMB and USD could impact reported financial results.
• Cybersecurity threats and potential IT system failures could disrupt operations.
• Difficulties in enforcing U.S. judgments against the company or its PRC-based management and assets.

Future Outlook

The company intends to use earnings for research and development, new product development, and production capacity expansion, and does not expect to pay cash dividends in the near future. Management plans to take remedial measures to address the material weakness in internal controls, including hiring qualified personnel and implementing training. The company will monitor its share price and take necessary actions to regain Nasdaq compliance. Future growth strategies include developing additional products through R&D or acquisitions and expanding sales networks, although these are subject to risks and uncertainties, including capital availability and market conditions.

Management Comments

• Management assessed the effectiveness of internal control over financial reporting and concluded it was not effective as of December 31, 2024, due to insufficient personnel with U.S. GAAP and SEC reporting knowledge.
• Management intends to cooperate with the SEC and other relevant authorities regarding the historical Tai He matter to protect investor interests.
• Management believes the company competes favorably based on its cost-effective product variety, distribution network, geographical advantages, economies of scale, quality standards, market-driven R&D, and experienced management.
• Management is authorized to repurchase up to $3 million of the company's outstanding Ordinary Shares under the Share Repurchase Plan.
• Management believes current cash, cash generated from operations, and capital market access will be sufficient for working capital needs for the next twelve months.

Industry Context

Meihua operates in the large and competitive global medical device industry, with a specific focus on disposable consumables. Its primary market is China, which has a rapidly evolving healthcare system influenced by government policies like the 'two-invoice system' and centralized procurement, increasing price pressure and favoring larger manufacturers. The company leverages its location in Touqiao Town, a designated medical device hub in China, for sourcing and operational efficiencies. Competition includes large domestic players like Weigao Group and Hongda Medical, as well as international companies. The industry is characterized by stringent regulations (Class I, II, III classifications, registration/licensing), emphasis on quality control (ISO 13485, CE marking, FDA registration), and ongoing technological advancements.

Comparison to Industry Standards

• Meihua positions itself as a provider of a 'one-stop service' for a wide range of disposable medical devices (over 1,700 SKUs), contrasting with some competitors like Allmed Medical Products Co., Ltd., which focuses more narrowly on wound care.
• The company competes with major Chinese medical device manufacturers such as Shandong Weigao Group, Jiangxi Hongda Medical Equipment Group, Henan Tuoren Medical Device Co., Ltd., Jiangxi Sanxin Medtec Co., Ltd., and Jiangxi 3L Products Group Co., Ltd.
• Meihua notes both competition and cooperation with these larger players, sometimes acting as a distributor for their products or having them distribute Meihua's products.
• Within its local hub of Touqiao Town, Meihua claims to be a top player with approximately 12% of total revenues and significantly larger scale (RMB 700M+ sales vs. RMB 100-150M for the next few largest) and product variety compared to local peers.
• Meihua's gross margin of 34% in 2024 could be compared to industry benchmarks for disposable medical device manufacturers, which can vary widely but often face pressure due to commoditization and centralized purchasing policies in markets like China.
• The company holds ISO 13485 certification, CE marking for certain products, and FDA registration for some Class I devices, aligning with international quality standards expected in the industry.

Corporate Governance

Legal Proceedings

• A legal proceeding, Zhu Cheng v. Jiangsu Yada Technology Group Co., Ltd., et al., resulted in a court ruling on September 19, 2024, requiring Jiangsu Yada to pay RMB 17 million plus interest (approximately $2.3 million claim).
• The company is appealing the ruling in the Zhu Cheng case, and the case is currently under second-instance trial.
• The company has recorded an estimated contingent liability of approximately $1.33 million related to this matter and provided a restricted deposit as security.
• The company may be subject to potential liabilities or litigation exposure related to the failure to disclose the Tai He Agreements at the time of the IPO in 2022.

Related Party Transactions

• Sales to Yangzhou Meihua Import and Export Co., Ltd. (controlled by Chairman's son) amounted to $768,553 in FY2024, with a receivable balance of $727,180 at year-end.
• Previous sales occurred to Shanghai Xinya Pharmaceutical Hanjiang Co., Ltd. (controlled by Chairman's son) in FY2022.
• A deposit of $9.2 million was paid to Ms. Fang Liu (Chairman's daughter) in 2023 related to the intent to purchase equity in Jiangsu Guomai; this transaction closed in November 2024 with a total payment of $13.7 million.
• Advances were made to related parties Zhongxiangxin ($6.85 million loan, collected post year-end) and Hainan Guoxie ($10.19 million advance) during FY2024.
• Short-term bank borrowings are guaranteed by major shareholders Yongjun Liu, Yin Liu, Kai Liu and subsidiary Yada.

Stakeholder Impact

• Shareholders face risks from potential delisting due to Nasdaq non-compliance, dilution from past convertible note conversions and potential future financing, negative impact from legal contingencies, and reduced governance protections due to controlled company status and home country rule exemptions.
• The historical Tai He fraud incident and ongoing internal control weaknesses could erode investor confidence.
• Employees benefit from PRC-mandated social security plans, but the company must ensure compliance with evolving labor laws.
• Customers rely on the company's product quality and one-stop service model; any quality issues or supply disruptions could negatively impact them.
• Suppliers face risks associated with the company's high accounts payable balance and lack of long-term contracts.

Next Steps

• The company plans to implement remedial measures to address the material weakness in internal control over financial reporting.
• The company will monitor its closing bid price and consider actions to regain compliance with Nasdaq's minimum bid price requirement before the June 2, 2025 deadline.
• The company will continue to pursue its appeal in the Zhu Cheng v. Jiangsu Yada et al. legal case.
• The company intends to continue its share repurchase program, subject to market conditions and other factors.
• The company plans to use earnings for research and development, new product development, and production capacity expansion.

Key Dates

Keywords

Medical Devices, Disposable Medical Supplies, China Healthcare, Medical Device Manufacturing, Class I Medical Device, Class II Medical Device, Class III Medical Device, Healthcare Consumables, Yangzhou, PRC Regulation, Nasdaq Listing, Internal Controls, Convertible Notes, Medical Device Distribution, Form 20-F